Table 1 Baseline characteristics of the study patients

 Female, n (%)

52 (65.0)

45 (55.6)

Age, years

56.56 ± 12.41

53.28 ± 11.90

Body mass index, kg/m²

22.16 ± 4.22

22.72 ± 3.57

Ex-smoker, n (%)

8 (10.0)

6 (7.4)

mMRC score(≥2)

48 (60.0)

45 (55.6)

CAT score

19.55 ± 7.26

19.15 ± 7.12

24-h sputum volume, mL

28.84 ± 40.94

29.74 ± 41.35

Etiology of bronchiectasis

 Postinfectious

38 (47.5)

30 (37.0)

 Idiopathic

42 (52.5)

51 (63.0)

 1

28 (35.0)

27 (33.3)

 2

41 (51.2)

34 (42.0)

 3

11 (13.8)

20 (24.7)

 1 lobe

15 (18.8)

18 (22.2)

 2–3 lobes

47 (58.8)

44 (54.3)

 4–6 lobes

18 (22.5)

19 (23.5)

Cystiform bronchiectasis, n (%)

33 (41.2)

44 (54.3)

Pseudomonas aeruginosa positive, n (%)

20 (25.0)

27 (33.3)

 Inhaled corticosteroids and long-acting β-agonist

45 (56.2)

56 (69.1)

 Inhaled short-acting β-agonist

20 (25.0)

15 (18.5)

 Inhaled anticholinergics

22 (27.5)

24 (29.6)

 Inhaled corticosteroids

17 (21.2)

11 (13.6)

Prednisone

2 (2.5)

3 (3.8)

Theophylline

6 (7.5)

4 (5.0)

 FVC, L

2.42 ± 0.94

2.32 ± 0.74

 FEV₁, L

1.56 ± 0.81

1.62 ± 0.73

 Predicted FEV₁, %

63.63 ± 26.28

60.23 ± 27.32

 FEV₁/FVC, %

64.39 ± 14.63

67.44 ± 16.49

 Inspiratory capacity, L

1.77 ± 0.70

1.88 ± 0.81

ESR, mm/h

25.39 ± 19.86

27.53 ± 24.07

CRP, mg/dL

16.99 ± 21.26

13.37 ± 17.12

Number of exacerbations in the last year

2 (2–3)

2 (2–3)

Bronchiectasis Severity Index

8.00 ± 4.27

8.43 ± 4.68